Important Safety Information

  • WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

    See full prescribing information for complete boxed warning

    Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early.

    • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
    • Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection. (See Serious Meningococcal Infections for additional guidance on the management of the risk of meningococcal infection.)
    • Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected.

    Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program.

Legal Notice

Alexion Pharmaceuticals, Inc. and its affiliated companies (together, “Alexion”, “we”, or “the Company”) provide this website as a source of general information about the Company. This website is linked to other websites and applications for mobile devices (“Applications”) provided by Alexion, which together with this website shall be referred to in this statement as the “Alexion Sites” or “Sites.”

PLEASE READ THIS LEGAL STATEMENT CAREFULLY BEFORE USING THE SITES. THIS STATEMENT INCLUDES:

  • TERMS OF USE
  • PRIVACY STATEMENT

BY USING THE SITES, YOU SIGNIFY YOUR ASSENT TO THESE TERMS. IF YOU DO NOT AGREE TO THESE TERMS, PLEASE DO NOT USE THE SITES.

Alexion has made reasonable efforts to ensure that information is complete and accurate when posted. However, Alexion makes no warranties or representations as to the completeness or accuracy of the information presented. Further, Alexion does not undertake any obligation to update any information that may change after posting. The medical information contained on the Sites is intended for informational purposes only. It is not a substitute for actual medical care. Persons requiring diagnosis or treatment or with questions specific to a single individual are urged to contact their local healthcare provider.

Terms of Use

Investors

The Alexion Sites contain forward-looking statements regarding Alexion's operations, financial condition, prospects, products, services, and strategies. Such forward-looking statements are based on estimates and projections about our industry, management's beliefs, and certain assumptions made by our management. Such statements are subject to certain factors which may cause Alexion's plans or results to differ from those expected, including, without limitation, decisions of regulatory authorities regarding marketing approval or material limitations on marketing of Alexion’s products; delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure; the possibility that results of clinical trials are not predictive of safety and efficacy results of Alexion’s products in broader patient populations in the disease studied or other diseases; the risk that acquisitions will not result in short-term or long-term benefits; the possibility that current results of commercialization are not predictive of future rates of commercialization; the risk that third parties will not agree to license any necessary intellectual property to Alexion on reasonable terms or at all; the risk that third party payors (including governmental agencies) will not reimburse for the use of Alexion’s products at acceptable rates or at all; the risk that estimates regarding the number of patients is inaccurate; our ability to successfully complete preclinical or clinical development of our products; our ability to expand the use of our product in other indications; and other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission. Alexion undertakes no obligation to update any of these forward-looking statements.

Restrictions on Use of Materials

The Sites are owned and operated by Alexion Pharmaceuticals, Inc. The contents of the Alexion Sites, such as text, graphics, images, logos, button icons, software and other material (the "Material") are protected under copyright, trademark and other laws. You may not copy, reproduce, republish, modify, upload, post, transmit, or distribute Material in any way, except that you may download one copy of the Material on any single computer for your personal use only, provided you keep intact all copyright and other proprietary notices. Use of the Material for any other purpose is a violation of Alexion's copyright and other proprietary rights. For purposes of these Terms of Use, the use of the Material or a modification of the Material on any other Site or networked computer environment is prohibited unless permission is obtained in writing from Alexion. You may not copy or adapt any Material we use to generate the web pages. This code is also protected by copyright and other laws.

Submissions

Alexion appreciates hearing from interested parties and welcomes your comments regarding Alexion's products or technologies, including Alexion's on-line services. However, Alexion's company policy does not allow it to accept or consider confidential creative ideas, suggestions, inventions, note drawings, concepts, materials or other information (collectively "Information") other than those it has specifically requested in writing. If you nonetheless send us any Information, it shall be deemed, and shall remain, the property of Alexion. None of the Information shall be subject to any obligation of confidence on the part of Alexion and Alexion shall not be liable for any use or disclosure of any Information. Without limitation of the foregoing, Alexion shall exclusively own all now known or hereafter existing rights to the Information and shall be entitled to unrestricted use of the Information for any purpose whatsoever, commercial or otherwise, without compensation to the provider of the Information.

You may use the Sites for lawful purposes. Alexion specifically prohibits use of the Sites for, and you agree not to: (i) use any device, software or routine to interfere or attempt to interfere with the proper working of the Sites; (ii) take any action that imposes an unreasonably large load on the Site’s infrastructure; (iii) decipher, decompile, disassemble, or reverse engineer any of the software comprising or in any way making up any part of the Sites, or attempt to do the same.

Jurisdictional Issues

Each website and its contents are intended for users in the jurisdiction indicated on each website and intended to comply with the laws and regulations in the jurisdiction indicated on the website, without regard to the conflict of law provisions thereof. Alexion makes no representation that Material is appropriate or available for use in other locations. By continuing use of a website, you are affirmatively consenting that your use hereof shall be governed by the laws applicable in the jurisdiction indicated on the website, excluding their conflict of law provisions. Those who choose to access a website from other locations do so on their own initiative and are responsible for compliance with local or national laws, if and to the extent local or national laws are applicable. Alexion reserves the right to limit provision of any product or service to any person, geographic region or jurisdiction and to limit the products or services that we provide.

Termination

This agreement is effective until terminated by either party. You may terminate this agreement at any time by destroying all materials obtained from any and all Alexion Site(s) and all related documentation and all copies and installations thereof, whether made under the terms of this agreement or otherwise. This agreement will terminate immediately without notice from Alexion if in Alexion's sole discretion you fail to comply with any term or provision of this Agreement. Upon termination, you must destroy all materials obtained from this Site and any and all other Alexion Site(s) and all copies thereof, whether made under the terms of this agreement or otherwise. Alexion reserves the right to alter or delete material from these Sites at any time and may, at any time, revise the terms of this Agreement by updating this posting. You are bound by any such revision and should therefore periodically visit this page to review the then current terms of this Agreement. The terms of use set forth for the Sites shall survive such termination, including without limitation the paragraphs headed "Investors,” "Restrictions on Use of Materials," "Submissions," "Jurisdictional Issues," "Termination,” and "Disclaimer."

Severability

If any of these Terms are held invalid or unenforceable by any court of competent jurisdiction, the other provisions of these Terms shall remain in full force and effect. If any provision of these Terms are held invalid or unenforceable only in part or degree, the remainder will continue in full force and effect to the extent not held invalid or unenforceable.

Disclaimer

The Sites are for informational purposes only. You should not use the information contained herein for diagnosing a health or fitness problem or disease. Alexion makes no warranties or representations as to its accuracy. Alexion assumes no liability or responsibility for any errors or omissions in the content of Sites. Alexion has not reviewed all of the sites that may be linked to its Sites, and is not responsible for the content of any off-Site pages or any other sites linked to these Sites. Your access to any off-Site pages is at your own risk. THE MATERIALS IN THESE SITES ARE PROVIDED "AS IS" AND WITHOUT WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED. TO THE FULLEST EXTENT PERMISSIBLE PURSUANT TO APPLICABLE LAW, ALEXION DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. ALEXION DOES NOT WARRANT THAT THE FUNCTIONS CONTAINED IN THE MATERIALS WILL BE UNINTERRUPTED OR ERROR-FREE, THAT DEFECTS WILL BE CORRECTED, OR THAT THIS SITE OR THE SERVER THAT MAKES IT AVAILABLE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ALEXION DOES NOT WARRANT OR MAKE ANY REPRESENTATIONS REGARDING THE USE OR THE RESULTS OF THE USE OF THE MATERIALS IN THESE SITES IN TERMS OF THEIR CORRECTNESS, ACCURACY, OR RELIABILITY. IN NO EVENT SHALL ALEXION BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, UNDER ANY LEGAL THEORY, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, YOUR ABILITY OR INABILITY TO USE THE SITES OR ANY INFORMATION CONTAINED THEREIN.

Trademark and Copyright Information

©Copyright 1998-2015 Alexion Pharmaceuticals, Inc. All rights reserved.

return to top
 

Important Safety Information

CLOSE

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

See full prescribing information for complete boxed warning

Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early.

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection. (See Serious Meningococcal Infections for additional guidance on the management of the risk of meningococcal infection.)
  • Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected.

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program.

Indications and Usage

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Atypical Hemolytic Uremic Syndrome (aHUS)

Soliris is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use

Soliris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Contraindications

Soliris is contraindicated in:

  • Patients with unresolved serious Neisseria meningitidis infection

  • Patients who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying Soliris treatment outweigh the risks of developing a meningococcal infection

Warnings and precautions

Other Infections

Soliris blocks terminal complement activation; therefore patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with Soliris may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenza type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenza type b (Hib) infections according to ACIP guidelines. Use caution when administering Soliris to patients with any systemic infection.

Monitoring Disease Manifestations After Soliris Discontinuation

Treatment Discontinuation for PNH

Monitor patients after discontinuing Soliris for at least 8 weeks to detect hemolysis.

Treatment Discontinuation for aHUS

After discontinuing Soliris, monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. In aHUS clinical trials, 18 patients (5 in the prospective studies) discontinued Soliris treatment. TMA complications occurred following a missed dose in 5 patients, and Soliris was reinitiated in 4 of these 5 patients.

Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis. In addition, the following changes in laboratory parameters may identify a TMA complication: occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during Soliris treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during Soliris treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during Soliris treatment.

If TMA complications occur after Soliris discontinuation, consider reinstitution of Soliris treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures.

Thrombosis Prevention and Management

The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Therefore, treatment with Soliris should not alter anticoagulant management.

Infusion Reactions

As with all protein products, administration of Soliris may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion reaction which required discontinuation of Soliris. Interrupt Soliris infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

Adverse Reactions

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea.

The most frequently reported adverse reactions in aHUS single arm prospective trials (≥20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia.

Please see full Prescribing Information for Soliris, including Boxed WARNING regarding serious meningococcal infection.